Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 8 de 8
1.
Nat Prod Res ; : 1-10, 2023 May 31.
Article En | MEDLINE | ID: mdl-37254994

During the chemical manufacturing control processing of new paclitaxel formulations, a photodegradation impurity called C3-C11 bridge-bond isomer appeared. Our work describes the synthesis, isolation, purification, and structural characterization methods using four spectroscopies: FT-IR, UV, NMR (1H and 13 C), and LC-MS. In addition, we discovered that the C3-C11 bridge-bond isomer can promote A549 cells pyroptosis, and increase pyroptosis-related proteins, including cleaved-caspase 3, cleaved-PARP, GSDME-N, and lactate dehydrogenase, thus making it anti-tumor effects. The study offered data suggesting that the C3-C11 bridge bond isomer may be used as an anti-tumour drug in the future.

2.
Phytomedicine ; 107: 154465, 2022 Dec.
Article En | MEDLINE | ID: mdl-36166943

BACKGROUND: Pueraria is the common name of the dried root of either Pueraria montana var. lobata (Willd.) Maesen & S.M.Almeida ex Sanjappa & Predeep (syn. Pueraria lobata (Willd.) Ohwi) or Pueraria montana var. thomsonii (Benth.) M.R.Almeida (syn. Pueraria thomsonii Benth.). Puerarin is a C-glucoside of the isoflavone daidzein extracted from Pueraria. It has been widely investigated to explore its therapeutic role in eye diseases and the molecular mechanisms. PURPOSE: To collect the available literature from 2000 to 2022 on puerarin in the treatment of ocular diseases and suggest the future required directions to improve its medicinal value. METHOD: The content of this review was obtained from databases such as Web of Science, PubMed, Google Scholar, China National Knowledge Infrastructure (CNKI), and the Wanfang Database. RESULTS: The search yielded 428 articles, of which 159 articles were included after excluding duplicate articles and articles related to puerarin but less relevant to the topic of the review. In eleven articles, the bioavailability of puerarin was discussed. Despite puerarin possesses diverse biological activities, its bioavailability on its own is poor. There are 95 articles in which the therapeutic mechanisms of puerarin in ocular diseases was reported. Of these, 54 articles discussed the various signalling pathways related to occular diseases affected by puerarin. The other 41 articles discussed specific biological activities of puerarin. It plays a therapeutic role in ophthalmopathy via regulating nuclear factor kappa-B (NF-ĸB), mitogen-activated protein kinases (MAPKs), PI3K/AKT, JAK/STAT, protein kinase C (PKC) and other related pathways, affecting the expression of tumour necrosis factor α (TNF-α), interleukin-1ß (IL-1ß), intercellular adhesion molecule-1 (ICAM-1), monocyte chemoattractant protein-1 (MCP-1), superoxide dismutase (SOD), B-cell lymphoma-2 (Bcl-2) and other cytokines resulting in anti-inflammatory, antioxidant and anti-apoptotic effects. The clinical applications of puerarin in ophthalmology were discussed in 25 articles. Eleven articles discussed the toxicity of puerarin. The literature suggests that puerarin has a good curative effect and can be used safely in clinical practice. CONCLUSION: This review has illustrated the diverse applications of puerarin acting on ocular diseases and suggested that puerarin can be used for treating diabetic retinopathy, retinal vascular occlusion, glaucoma and other ocular diseases in the clinic. Some ocular diseases are the result of the combined action of multiple factors, and the effect of puerarin on different factors needs to be further studied to improve a more complete mechanism of action of puerarin. In addition, it is necessary to increase the number of subjects in clinical trials and conduct clinical trials for other ocular diseases. The information presented here will guide future research studies.


Isoflavones , Ophthalmology , Pueraria , Anti-Inflammatory Agents/metabolism , Antioxidants/pharmacology , Chemokine CCL2/metabolism , Glucosides/metabolism , Humans , Intercellular Adhesion Molecule-1/metabolism , Interleukin-1beta/metabolism , Isoflavones/therapeutic use , Mitogen-Activated Protein Kinases/metabolism , NF-kappa B/metabolism , Phosphatidylinositol 3-Kinases/metabolism , Protein Kinase C/metabolism , Proto-Oncogene Proteins c-akt/metabolism , Proto-Oncogene Proteins c-bcl-2/metabolism , Pueraria/chemistry , Superoxide Dismutase/metabolism , Tumor Necrosis Factor-alpha/metabolism
3.
Biomed Pharmacother ; 129: 110469, 2020 Sep.
Article En | MEDLINE | ID: mdl-32768956

The infections caused by Herpes simplex viruses (HSV-1 and -2) are seriously endangering the health of all human beings. Once infected with these two viruses, it will cause life-long latency in the host, and the continuous recurrence of the infection will seriously affect the quality of life. Moreover, infections with HSV-1 and HSV-2 have been reported to make the body susceptible to other diseases, such as Alzheimer's disease and HIV. Thus, more attention should be paid to the development of novel anti-HSV drugs. Polysaccharides obtained from medicinal plants and microorganism (both land and sea) are reported to be promising anti-herpes substances. However, their antiviral mechanisms are complex and diverse, which includes direct inhibition of virus life cycle (Adsorption, penetration, genetic material and protein synthesis) and indirectly through improving the body's immunity. And each step of the research processes from extraction to structural analysis contributes to the result in terms of antiviral activity. Therefore, The complex mechanisms involved in the treatment of Herpes simplex infections makes development of new antiviral compounds is difficult. In this paper, the mechanisms of polysaccharides in the treatment of Herpes simplex infections, the research processes of polysaccharides and their potential clinical applications were reviewed.


Antiviral Agents/pharmacology , Fungal Polysaccharides/pharmacology , Herpes Simplex/drug therapy , Herpesvirus 1, Human/drug effects , Herpesvirus 2, Human/drug effects , Plant Extracts/pharmacology , Plants, Medicinal , Polysaccharides, Bacterial/pharmacology , Polysaccharides/pharmacology , Animals , Antiviral Agents/isolation & purification , Fungal Polysaccharides/isolation & purification , Herpes Simplex/virology , Herpesvirus 1, Human/growth & development , Herpesvirus 1, Human/pathogenicity , Herpesvirus 2, Human/growth & development , Herpesvirus 2, Human/pathogenicity , Humans , Plant Extracts/isolation & purification , Plants, Medicinal/chemistry , Polysaccharides/isolation & purification , Polysaccharides, Bacterial/isolation & purification
4.
Carbohydr Polym ; 246: 116589, 2020 Oct 15.
Article En | MEDLINE | ID: mdl-32747248

Inulin (IN), a fructan-type plant polysaccharide, is widely found in nature. The major plant sources of IN include chicory, Jerusalem artichoke, dahlia etc. Studies have found that IN possessed a wide array of biological activities, e.g. as a prebiotic to improve the intestinal microbe environment, regulating blood sugar, regulating blood lipids, antioxidant, anticancer, immune regulation and so on. Currently, IN is widely used in the food and pharmaceutical industries. IN can be used as thickener, fat replacer, sweetener and water retaining agent in the food industry. IN also can be applied in the pharmaceutics as stabilizer, drug carrier, and auxiliary therapeutic agent for certain diseases such as constipation and diabetes. This paper reviews the physiological functions of IN and its applications in the field of pharmaceutics, analyzes its present research status and future research direction. This review will serve as a one-in-all resource for the researchers who are interested to work on IN.


Antineoplastic Agents/pharmacology , Antioxidants/pharmacology , Hypoglycemic Agents/pharmacology , Immunologic Factors/pharmacology , Inulin/pharmacology , Laxatives/pharmacology , Animals , Antineoplastic Agents/chemistry , Antineoplastic Agents/isolation & purification , Antineoplastic Agents/metabolism , Antioxidants/chemistry , Antioxidants/isolation & purification , Antioxidants/metabolism , Blood Glucose/metabolism , Cichorium intybus/chemistry , Dahlia/chemistry , Drug Carriers/chemistry , Excipients/chemistry , Excipients/isolation & purification , Helianthus/chemistry , Humans , Hypoglycemic Agents/chemistry , Hypoglycemic Agents/isolation & purification , Hypoglycemic Agents/metabolism , Immunologic Factors/chemistry , Immunologic Factors/isolation & purification , Immunologic Factors/metabolism , Inulin/chemistry , Inulin/isolation & purification , Inulin/metabolism , Laxatives/chemistry , Laxatives/isolation & purification , Laxatives/metabolism , Lipids/blood , Prebiotics/administration & dosage , Sweetening Agents/chemistry , Sweetening Agents/isolation & purification
5.
Drug Dev Ind Pharm ; 46(6): 916-930, 2020 Jun.
Article En | MEDLINE | ID: mdl-32362146

Tumor invasion and metastasis are the nodus of anti-tumor. Epithelial cell-mesenchymal transition is widely regarded as one of the key steps in the invasion and metastasis of breast cancer. In this study, GGP modified daunorubicin plus dioscin liposomes are constructed and characterized. GGP modified daunorubicin plus dioscin liposome has suitable particle size, narrow PDI, zeta potential of about -5 mV, long cycle effect, and enhanced cell uptake due to surface modification of GGP making the liposome could enter the inside of the tumor to fully exert its anti-tumor effect. The results of in vitro experiments show that the liposome has superior killing effect on tumor cells and invasion. In vivo results indicate that the liposome prolongs the drug's prolonged time in the body and accumulates at the tumor site with little systemic toxicity. In short, the targeted liposome can effectively inhibit tumor invasion and may provide a new strategy for the treatment of invasive breast cancer.


Breast Neoplasms , Daunorubicin/chemistry , Diosgenin/analogs & derivatives , Epithelial-Mesenchymal Transition , Breast Neoplasms/drug therapy , Cell Line, Tumor , Diosgenin/chemistry , Humans , Liposomes
7.
Biomed Pharmacother ; 118: 109335, 2019 Oct.
Article En | MEDLINE | ID: mdl-31452513

In this study, we aimed to evaluate the antiviral effect of total flavonoids extracted from Robinia pseudoacacia cv. idaho (RPTF) in vivo and its toxicity on rats with oral gavage. RPTF was prepared by percolation with 70% ethanol for 24 h and its antiviral effect on different kinds of viruses was evaluated in vitro by MTT staining. The long-term toxicity of RPTF on rats was evaluated through the detection of general behavior, body weight, food intake and related organ tissue sections of experimental animals. We found that RPTF produced significantly inhibitory effects on HSV-1 and EV-71 viruses with the therapeutic index TI values 113.8 and 46.2, respectively. Moreover, toxicity evaluation in vivo showed no significantly adverse effects in rats, indicating that RPTF was safe in use. In conclusion, we demonstrated that RPTF, natural compounds in the Chinese traditional medicine, could act as promising and effective antiviral therapeutics with relative safety in use.


Antiviral Agents/pharmacology , Antiviral Agents/toxicity , Flavonoids/pharmacology , Flavonoids/toxicity , Robinia/chemistry , Toxicity Tests , Animals , Antiviral Agents/isolation & purification , Body Weight/drug effects , Feeding Behavior/drug effects , Female , Flavonoids/isolation & purification , Liver/drug effects , Liver/pathology , Male , Rats, Wistar
8.
Pharm Dev Technol ; 24(9): 1164-1174, 2019 Nov.
Article En | MEDLINE | ID: mdl-31340709

We prepared octreotide (OCT)-modified curcumin plus docetaxel micelles to enhance active targeting and inhibit tumor metastasis by destroying vasculogenic mimicry (VM) channels. Soluplus was applied as an amphiphilic material to form micelles via film dispersion. The cytotoxic effects, active cellular targeting, and inhibitory effects on metastasis were systematically evaluated in vitro using A549 cells, and in vivo antitumor effects were evaluated using xenograft tumor-bearing mice. In vitro assays indicated that the OCT-modified curcumin plus docetaxel micelles showed robust cytotoxicity on A549 cells and effectively inhibited VM channels and tumor metastasis. Studying the mechanism of action indicated that OCT-modified curcumin plus docetaxel micelles downregulated MMP-2 and HIF-1α. In vivo assays indicated that OCT-modified curcumin plus docetaxel micelles increased drug accumulation at tumor sites and showed obvious antitumor efficacy. The developed OCT-modified curcumin plus docetaxel micelles may offer a promising treatment strategy for non-small-cell lung cancer.


Antineoplastic Agents/administration & dosage , Carcinoma, Non-Small-Cell Lung/drug therapy , Curcumin/administration & dosage , Docetaxel/administration & dosage , Lung Neoplasms/drug therapy , Octreotide/administration & dosage , A549 Cells , Animals , Antineoplastic Agents/pharmacokinetics , Antineoplastic Agents/therapeutic use , Curcumin/analogs & derivatives , Curcumin/pharmacokinetics , Curcumin/therapeutic use , Docetaxel/pharmacokinetics , Docetaxel/therapeutic use , Drug Carriers/chemistry , Drug Delivery Systems , Humans , Mice, Inbred BALB C , Mice, Nude , Micelles , Octreotide/analogs & derivatives , Octreotide/pharmacokinetics , Octreotide/therapeutic use , Polyethylene Glycols/chemistry , Polyvinyls/chemistry
...